Nacubactam
- Generic Name
- Nacubactam
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16N4O7S
- CAS Number
- 1452458-86-4
- Unique Ingredient Identifier
- 832O37V7MZ
- Background
Nacubactam is under investigation in clinical trial NCT03174795 (A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection).
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
- Conditions
- Gram-negative Bacterial Infections
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT03182504
- Locations
- ๐บ๐ธ
Pulmonary Associates Clinical Trials (PACT), Phoenix, Arizona, United States
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT03174795
- Locations
- ๐บ๐ธ
eStudySite, La Mesa, California, United States
๐ญ๐บSemmelweis University, First Dept of Medicine, Budapest, Hungary
๐บ๐ธJacksonville Center For Clinical Research, Jacksonville, Florida, United States
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT02975388
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT02972255
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
๐บ๐ธCovance Clinical Research Unit, Inc, Madison, Wisconsin, United States
A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595
- Conditions
- Healthy VolunteersBacterial Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02134834
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.